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Abstract
objectives: Study to compare the effects of tibolone and raloxifene on health related 
quality of life, sexuality and vaginal atrophy. 
Methods: A double-blind, randomized study was conducted in 308 osteopenic, but 
otherwise healthy, postmenopausal women (mean age 66 years) who received tibolone 
1.25 mg/day or raloxifene 60 mg/day for 2 years. Health related quality of life was 
assessed by the Women’s Health Questionnaire (WHQ), sexual function by the McCoy 
Female Sexuality Questionnaire (MFSQ) and vaginal atrophy by assessing the Karyopyc-
notic Index (KI) and Vaginal Maturation (VM). 
results: At week 104, the tibolone group showed a trend towards an improved health 
related quality of life (HRQoL) mean score in eight out of nine WHQ domains. HRQoL 
scores approximated values for premenopausal women, being pre-defined as “clinically 
relevant”. The raloxifene group showed a trend to a diminished HRQoL mean score from 
baseline to week 104. No difference could be assessed between the tibolone and 
raloxifene group in mean total score and separate domains scores of the MFSQ, except 
for the vaginal lubrication domain (p= 0.037). The increase in KI and VM was statistically 
significantly greater with tibolone than with raloxifene (for both KI and VM p<0.0001). 
Tibolone and raloxifene were equally well tolerated. 
conclusions: In older postmenopausal women, tibolone treatment showed a trend 






















































The publication of the Women’s Health Initiative1 and Million Women Study2 studies led 
to a change in thinking about the use of hormone therapy (HT) for osteoporosis preven-
tion and prompted consideration of other available strategies such as bisphosphonates, 
parathyroid hormone, selective estrogen receptor modulators (SERMs) and the selec-
tive tissue estrogenic activity regulator (STEAR) tibolone.3,4
Tibolone regulates estrogenic activity in a tissue selective manner, resulting in 
estrogenic activity in certain tissues, like bone, vagina and the brain, hereby improving 
vasomotor symptoms, whilst avoiding it in the endometrium and breast.5 This tissue 
selective action of tibolone and its metabolites is a result of a number of mechanisms, 
depending on the target tissue, and include local metabolism, inactivation or activation 
of steroid metabolizing enzymes and differential receptor binding. 
In contrast, the tissue selective action of the SERMs is solely a consequence of receptor 
binding which results in estrogenic agonist or antagonist effects, depending on the 
target tissue. Tibolone therefore differs from the SERMs, not only because it has no 
antagonistic effect on the estrogen receptor, but also because it acts via a variety of 
mechanisms.6
Efficacy in the prevention and treatment of osteoporosis in postmenopausal women has 
been confirmed in randomized controlled studies with raloxifene7-11 and with a standard 
2.5 mg/day dose of tibolone.12-14 A lower dose of 1.25 mg/day tibolone has also proved 
consistently effective15-17 and is now considered to be the optimal dose for osteoporosis 
prevention. Raloxifene has the benefit of reducing the risk of invasive breast cancer, 
but suggestions that it has beneficial effects on coronary heart disease have not been 
confirmed.18 
In common with conventional estrogen and estrogen-progestogen therapy (EPT), 
tibolone relieves climacteric symptoms and vaginal atrophy19-22 and there is evidence 
that is has beneficial effects on sexual function and mood.23 Unfortunately, SERMs such 
as raloxifene may cause or exacerbate hot flushes.8,9,24 This may deter many postmeno-
pausal women, as the most common reason for taking HT is to alleviate climacteric 
symptoms. 
The primary objective of the Study of Tibolone’s Effects on osteoPenia (STEP) study was 
to compare the effects of tibolone 1.25 mg/day and raloxifene 60 mg/day on lumbar 
vertebrae bone mineral density (BMD) in osteopenic women. These findings have been 
published elsewhere.25,26 The secondary objectives include determination of health- 




Osteopenic, but otherwise healthy, postmenopausal women (aged 60-79 years) were 


























study conducted in eight centers in Australia, France, Germany, Italy and the USA. The 
study was conducted in compliance with the Declaration of Helsinki, International Confer-
ence of Harmonisation guidelines and Good Clinical Practice; the protocol was approved 
by the Independent Ethics Committee or Institutional Review Board of each center. All 
women provided written informed consent. The women were recruited through investiga-
tor’s practices, referrals and advertisements in the local press and broadcast media. 
Women were included if they had been amenorrheic for at least a year (if the date of last 
menstruation was unclear because of perimenopausal HT use, HT had to have been used 
for at least 2 years), were ambulatory, and had a lumbar vertebrae bone mineral density 
of -2.5 to -1.0 standard deviations of the T-score and a body mass index of >19 to ≤30 
kg/m2. Exclusion criteria included history/presence of malignancy (or current suspicion 
of malignancy) or thromboembolic disorders, abnormal Pap smear or transvaginal ultra-
sound (TVUS), undiagnosed abnormal vaginal bleeding in the previous year, uncon-
trolled hypertension, type I diabetes mellitus, serious decompensated renal or hepatic 
disease, abnormal laboratory values, X-ray showing symptomatic vertebral fracture, 
history of bilateral hip replacement, bone disease other than osteoporosis, and use of 
>20 cigarettes or 4 alcoholic drinks per day. Other reasons for exclusion included current or 
recent prolonged use of drugs that affect steroid pharmacokinetics, use of anabolic ster-
oids, calcitonin or raloxifene in the last 6 months, use of alendronate or risedronate for >6 
months (12 month washout if >6 months), use of etidronate (6 or 12 month washout 
if used for ≤1 year or >1 year, respectively), use of fluoride for ≥2 weeks, systemic gluco-
corticoid treatment for >1 month in the past 6 months, a change in thyroid medication in 
the last 6 weeks, and ever use of estrogen and/or progestin implants. Washout periods 
were 8 weeks for oral estrogen and/or progestin, 4 weeks for transdermal HT or local 
estrogen, and 20 weeks for medroxyprogesterone acetate-containing contraceptives. 
treatment
The women were randomized to treatment with oral tibolone 1.25 mg or raloxifene 60 
mg once daily for 2 years. Treatment was taken in the evening and a double-dummy 
technique was used to preserve blinding. Concomitant use of sex hormones or 
anabolics, hepatic enzyme inducing drugs, cholestyramine, colestipol, coumarin prod-
ucts or medication for osteoporosis (except calcium/vitamin D) was not permitted.
Assessments
Following screening and baseline visits, assessments were performed after 4, 12, 24, 52, 
76 and 104 weeks of treatment. 
Health related quality of life, assessed by the Women’s Health Questionnaire (WHQ) was 
measured at baseline and each follow up visit. The WHQ is a self-administered question-
naire consisting of 36 items, which are divided into 9 subscales: somatic symptoms, 
depressed mood, memory/concentration, anxiety/fears, sexual behavior, vasomotor 
symptoms, sleep problems, menstrual symptoms and attractiveness.27 Changes from 
baseline in the various WHQ domains are expressed in terms of clinical relevance when 





















































Sexual function was assessed by the McCoy Female Sexuality Questionnaire Short Form 
(MFSQ) at baseline and at each follow up visit. The MFSQ questionnaire consists out of 
four domains created from 9 items: sexual interest, vaginal lubrication, orgasm and 
sexual partner. A global score is based on the sum of all 9 items.28
A vaginal smear was obtained at baseline and after 52 and 104 weeks and vaginal atrophy 
was assessed by the Karyopycnotic Index (KI) and Vaginal Maturation (VM). Vaginal smears 
were analyzed by a central cytology/pathology laboratory. The percentage of superficial, 
intermediate and parabasal cells in the smear was determined. The KI was defined as 
the percentage of superficial cells. VM was calculated by multiplying the percentage of 
superficial cells by 1, intermediate cells by 0.5 and parabasal cells by 0 and summing 
the total. VM values ranged from 0, when only parabasal cells were present (atrophic 
specimen), to 100 when only superficial cells were present (mature specimens). Physical 
and gynecological examinations, including TVUS and mammography were performed 
at baseline and after 52 and 104 weeks. Information on possible adverse events was 
obtained at each visit.
statistical analyses
Analyses were based on the Intent-to-treat principle (ITT analysis): all subjects treated 
who had at least one post-baseline assessment were included in the efficacy analysis. 
WHQ and MFSQ analyses were performed using the non-parametric Wilcoxon rank test 
using a complete case analysis (i.e. domain and global scores were only calculated when 
all the items were available for the subject). Statistical analyses of KI and VM were per-
formed by an Analysis of Variance (ANOVA) model using the last observation carried 
forward (LOCF) approach. An imputed case analysis was used to account for subjects 
who did not complete the final visit at week 104. All tests were two sided with statistical 
significance defined as P<0.05. Analyses were performed using SAS 8.2 software.
results
In total, 310 women with a mean age of 66 years were enrolled and randomized to trial 
medication of which finally 153 in the tibolone group and 155 in the raloxifene group 
commenced treatment. The number of subjects at each stage of the study and their base-
line demographic characteristics are shown in Figure 1 and in Table 1. There were no 
relevant differences between the groups. The ITT population consisted of 115 subjects on 
tibolone and 120 on raloxifene. The study was discontinued prematurely by 52 subjects 
in the tibolone group and 50 in the raloxifene group, resulting in 101 completers on tibo-
lone and 105 on raloxifene. 
Health-related quality of life
Baseline demographic data relating to quality of life, such as marital status, total family 
income, level of formal education and occupation, were comparable between the two 
treatment groups. The majority of women were married, retired, had attended primary 


























figure 1. Subject disposition
table 1.  Demographic characteristics (AST)
	
 tibolone raloxifene 










Tibolone showed statistically significant benefits (lower mean score) over raloxifene on 
a number of health-related quality of life domains (Table 2): In the raloxifene group, the 





















































tibolone group reflecting a worsening of vasomotor symptoms in the raloxifene group 
during treatment. The differences were statistically significant at week 12 (p=0.005), 
week 24 (p=0.001) and week 52 (p=0.002) in favor of the tibolone group. Other domains 
showing statistically significant differences in favor of the tibolone group included 
depressed mood at week 24 (p=0.016) and week 104 (p<0.001), sexual behavior at week 
52 (p=0.006) and week 104 (p=0.011), somatic symptoms at week 52 (p=0.048) and 
attractiveness at week 12 (p=0.04). There were no statistically significant advantages for 
raloxifene on any of the subscales. 
No clinical relevant changes based on normative WHQ domain scores for premeno-
pausal women when compared to baseline were found in any of the two groups. 
However, tibolone treatment resulted in a trend towards an improved quality of life from 
baseline to week 104 on eight of the nine WHQ subscales: somatic symptoms, depressed 
mood, memory/concentration, anxiety/fears, sexual behavior, vasomotor symptoms, 
sleep problems and menstrual symptoms. In contrast, women treated with raloxifene 
showed a trend towards a poorer health-related quality of life over the same time period 
on six subscales: somatic symptoms, depressed mood, sexual behavior, vasomotor 
symptoms, menstrual problems and attractiveness. A clinically relevant “worsening’ 
was found for the attractiveness domain in the raloxifene group from week 52 
onwards. 
sexual function
Only 58 (38%)women in the tibolone group and 65 (42%) women in the raloxifene group 
provided data for the MFSQ. The main reason for not completing this questionnaire was 
absence of sexual activity. Figure 2 shows the scores in each of the four domains and the 
total score at baseline and after 52 and 104 weeks of treatment. Generally, there was little 
to no difference between the tibolone and raloxifene group in mean and median scores 
for the 4 domains (sexual interest, sex with partner, orgasm and vaginal lubrication) and 
the global score of the McCoy Female Sexuality Questionnaire, Short Form at any of the 
post-baseline visits. 
A statistically significant difference in favor of the tibolone group was only found for the 
vaginal lubrication domain at week 52 where for tibolone a 47% improvement and for 
raloxifene a 8% improvement from baseline was observed (p=0.037). 
A post-hoc separate item analysis showed statistically significant differences in favor of 
the tibolone treated women on a few questions including the presence of sexual thoughts 
and fantasies (week 104: p=0.047), feeling aroused/excited (week 24: p=0.038) and a 
decrease in pain during intercourse (week 52: p=0.02). 
vaginal atrophy
There were no statistically significant differences between the tibolone and raloxifene 
groups in baseline KI (4.69% and 4.92%, respectively) or VM (18.06% and 17.74%, respec-
tively). Vaginal atrophy was improved by tibolone, but remained unchanged in the 
raloxifene group. The increase from baseline in both KI and VM was statistically 



























figure 2. Mean MFSQ actual domain scores and global score (center) at baseline and after 52 and 104 weeks 
of treatment with tibolone or raloxifene: ITT population (complete case analysis)
vaginal lubrication (range 2-14) sexual interest (range 4-28)
sexual partner (range 2-14) oragsm (range 1-7)
Baseline                Week 52               Week 104   Baseline                Week 52               Week 104   
Baseline                Week 52               Week 104   Baseline                Week 52               Week 104   
MfsQ global score (range 9-63)




















































































Tibolone and raloxifene were equally well tolerated. The incidence of adverse events 
(AEs) was similar in both groups. AEs that were reported in >10% of subjects in any or 
both of the two treatment groups were: muscle spasms (tibolone 25.5%; raloxifene 
26.5%), arthralgia (tibolone 16.3%; raloxifene 12.9%), hyperhidrosis (tibolone 13.7%; 
raloxifene 16.1%), back pain (tibolone 13.1%; raloxifene 11.6%), weight increase (tibolone 
12.4%; raloxifene 13.5%), nasopharyngitis (tibolone 11.1%; raloxifene 11.6%), meno-
pausal symptoms (tibolone 10.5%; raloxifene 18.1%), hypertension (tibolone 11.8%; 
raloxifene <10%), arthralgia (tibolone <10%; raloxifene 12.9%). Adverse events classified 
as menopausal symptoms (including night sweats and hot flushes) occurred in 23 
women (15%) treated with tibolone compared with 37 (24%) treated with raloxifene. 
AEs accounted for the withdrawal of 27.5% of women in the tibolone group and 23.2% 
in the raloxifene group; the most common reasons for withdrawal were reproductive 
system and breast disorders (9.2%), weight increase (3.9%) and gastrointestinal dis- 
orders (3.9%) with tibolone and vascular disorders (4.5%) and weight increase (3.2%) 
with raloxifene. One subject in the raloxifene group died after a fall causing a sub- 
arachnoid bleeding. Drug-related (defined as definitely, probably or possibly related 
to study medication according to the investigators) serious adverse events (each of 
which occurred in one subject) were postmenopausal bleeding, uterine polyp/vaginal 
bleeding, endometrial disorder, hydrometra, meningioma, breast cancer and transient 
ischemic attack in the tibolone group and benign breast neoplasm, dystonia and 
exanthema/pruritis in the raloxifene group.
There were no clinically relevant differences between the groups with regard to physical 
and gynecological examinations, cervical Pap smear, TVUS, mammography, vital signs 
or laboratory parameters. Mean double layer endometrial thickness for tibolone and 
raloxifene at week 52 were: 1.50 mm and 0.40 mm respectively and at week 104: 1.34 and 
0.29 respectively. 
Maturation value    *p<.0001 vs raloxifene
figur 3. Mean change from baseline in Karyopycnotic Index and Vaginal Maturation after 52 and 104 
weeks of treatment with tibolone (n=112) or raloxifene (n=118): ITT population (LOCF)
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discussion
The recent controversies surrounding conventional HT and the risk of breast cancer and 
cardiovascular disease have resulted in many women stopping treatment.29,30 The need 
remains, however, for effective ways of relieving vasomotor symptoms, improving 
quality of life and preventing mediate to long term consequences of menopause such 
as vaginal atrophy and osteoporosis. Amongst the alternative options are the STEAR 
tibolone and the SERM raloxifene, which have been directly compared in this 2 year 
study in osteopenic postmenopausal women. Tibolone 1.25 mg/day effectively prevented 
bone loss and resulted in a larger increase of BMD at the lumbar spine and hip than 
standard dose raloxifene and less risk of ongoing bone loss from the lumbar spine.25 
There were a number of other distinctions between the two treatments. Tibolone 
improved health-related quality of life, with WHQ values approximating those for 
premenopausal women, whilst women treated with raloxifene showed a trend towards 
a poorer quality of life.27 Changes from baseline of a few WHQ domains were statisti-
cally significantly larger in favor of the tibolone group when compared to the raloxifene 
group, particularly the sexual behavior, attractiveness and vasomotor symptoms all 
showed a statistically significant improvement from baseline. Of note, however, is that 
results of questionnaires, especially when analyzed at various time points during the 
study, should be interpreted with caution as a statistically significant difference at only 
one measured time point without being maintained over the duration of the study and/
or without approximating values predefined as being clinically relevant, are likely to be 
subject to chance. Vasomotor symptoms were consistently worse with raloxifene 
throughout the study. This was confirmed by the higher incidence of vasomotor 
symptoms reported as adverse events with raloxifene. Vasomotor effects, which are 
experienced by more than 80% of untreated postmenopausal women, are often 
considered the most disturbing symptom of the menopause.30,31 Although this is the first 
direct comparison of the efficacy of tibolone and raloxifene in postmenopausal women, 
studies in estrogen-deficient rats have shown that tibolone, in common with estrogen 
and clonidine, restored tail temperature to that seen in non-ovariectomized animals, 
whilst no change occurred with raloxifene.32 Previous clinical studies have demonstrated 
that raloxifene causes or worsens vasomotor symptoms, whilst tibolone provides 
a similar level of relief to that achieved with conventional HT.19,33,34 The lower 1.25 mg 
dose of tibolone, as used in the current study, has also been shown to be effective in 
controlling hot flushes, sweating and other symptoms, resulting in significantly greater 
relief than that seen with placebo.21,22
No statistically significant differences between the two treatment groups regarding 
changes in sexual function, measured by the MFSQ total score and domain scores, could 
be observed except for some separate item scores for the tibolone treated women. This 
is remarkable as it is thought that the reduction in sex hormone binding globulin levels 
(resulting in increased free testosterone) caused by tibolone, together with the direct 
androgenic effects of the Δ4 metabolite, contribute to the beneficial effects on sexual 





















































In the current study, measures of vaginal atrophy showed improvement with tibolone, 
whilst there were no meaningful changes in the raloxifene group. Both KI and VM were 
increased with tibolone, resulting in a significant difference from the raloxifene-treated 
women. Most likely the improvement in the vaginal lubrication domain of the MFSQ is 
a result of the improved condition of the vaginal tissue after estrogenic exposure.
Tibolone and raloxifene were equally well tolerated in these elderly postmenopausal 
women. A number of previous studies have also directly compared various safety and 
tolerability aspects of tibolone and raloxifene, although all were conducted with the 
higher 2.5 mg/day dose of tibolone. In this study neither tibolone nor raloxifene were 
associated with any significant changes in endometrial thickness or unscheduled 
bleeding/spotting confirming their favorable endometrial profile indicated in previous 
comparative studies.35 It must be emphasized that this study was not powered to 
identify the significance of less common serious AEs, such as VTE and stroke. 
A strength of this study is that this is the first randomized controlled study comparing 
tibolone with raloxifene on various measures of menopausal health in elderly women. 
In addition we collected sexuality and quality of life data over a longer time period.
Limitations of this study are that the actual number of subjects (310) was somewhat 
lower than the planned number of 325 and that for only one third of the women 
evaluable MFSQ data were available. For the primary efficacy parameter on bone the 
difference between groups was large enough to detect a statistical significant difference. 
However, for the secondary endpoints concerning behavioral science, the study popula-
tion might not have been large enough to pick up clinically relevant differences 
especially because quality of life and sexuality are influenced by so many other factors 
than pharmaceutical treatment only. For the MFSQ analyses the two study groups 
were not entirely comparable at baseline. As only women who were sexually active 
completed the questionnaires a selection has taken place which might have prevented 
to measure more extreme changes in the MFSQ during the trial period. Moreover, the 
tibolone group had higher baseline scores on the MFSQ. In which way higher or lower 
scores at baseline influences treatment outcomes is a topic for further investigation. 
In conclusion, tibolone showed benefits over raloxifene in certain aspects influencing 
quality of life which concern: depressed mood, presence of somatic symptoms, improve-
ment of vasomotor symptoms, feelings of attractiveness, improvement of sexual 
function specifically due to improvement of vaginal lubrication, reduction of painful 
intercourse, presence of sexual thoughts and improvement of sexual arousal. In addi-
tion to the bone preserving effects of both treatments, the above aspects make tibolone 
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